Navigation Links
Protox Announces Publication in Journal of the National Cancer,Institute Supporting PRX302 as Treatment for Prostatic Diseases

ucted by Dr Arthur Frankel and his team at the Cancer Research Institute of Scott and White Memorial Hospital in collaboration with scientists at Protox and Johns Hopkins University. Key findings include: human prostate cancer cells are significantly more sensitive to PRX302 in the presence of active PSA; PRX302 was totally resistant to thrombin, matrix metalloprotease 7 (MMP-7), human kallikrein 1 (hk1) and human kallikrein 2 (hk2) activation; and among the normal cells tested, the PSA-producing prostate epithelial cells were the only normal cells that were highly sensitive to PRX302.

Both publications demonstrated that the PSA-activated strategy for PRX302 has a number of inherent advantages as a therapeutic strategy for locally recurrent prostate cancer and BPH.

About Protox

Protox Therapeutics is a leader in advancing novel, targeted protein toxin therapeutics for treatment of cancer and other proliferative diseases. The company is actively developing two distinct but complementary platforms, INxin(TM) and PORxin, and currently has three clinical programs in
development. A Phase IIa clinical trial into the use of PRX321 (INxin) for the treatment of primary brain cancer has been completed and the drug has received Fast Track Designation and Orphan Drug Status from the US FDA. In addition, a Phase I trial has been completed for PRX321 to treat patients with renal cell carcinoma and non-small cell lung cancer. Patient enrolment is underway for a Phase I clinical study into the use of PRX302 (PORxin) to treat localized prostate cancer. PRX302 has also been approved by Health Canada to commence a Phase I clinical study for the treatment of benign prostatic hyperplasia.

NO REGULATORY AUTHORITY HAS APPROVED OR DISAPPROVED THE CONTENT OF THIS RELEASE. THE TSX VENTURE EXCHANGE DOES NOT ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

Certain st
'"/>




Page: 1 2 3

Related medicine technology :

1. Protox Announces Positive Clinical Data from Prostate Cancer Study
2. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
3. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
6. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
7. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
9. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
10. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
11. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
Post Your Comments:
(Date:7/31/2014)... 2014  Zacks.com announces the list of stocks featured in ... discuss the latest news and events impacting stocks and the ... (Nasdaq: BIIB - Free Report ), Gilead (Nasdaq: ... - Free Report ), AbbVie (NYSE: ABBV - Free ... ). Today, Zacks is promoting its ,Buy, stock ...
(Date:7/31/2014)... July 31, 2014 Vermillion, Inc. (NASDAQ: VRML), a ... will hold a conference call on Thursday, August 14, 2014, ... second quarter ended June 30, 2014. Financial results will be ... Vermillion,s Chairman, President and CEO James LaFrance ... period. Date: Thursday, August 14, 2014 Time: 4:30 ...
(Date:7/31/2014)... , July 31, 2014 TB Alliance, ... developing better, faster and affordable treatments, announced the ... Vice President, External Affairs. Mr. Brock comes to ... of Major Donor Relations for WWF International (formerly ... role, Mr. Brock will guide the TB Alliance,s ...
Breaking Medicine Technology:The Zacks Analyst Blog Highlights: Biogen, Gilead, Puma Biotechnology, AbbVie and Celgene 2The Zacks Analyst Blog Highlights: Biogen, Gilead, Puma Biotechnology, AbbVie and Celgene 3The Zacks Analyst Blog Highlights: Biogen, Gilead, Puma Biotechnology, AbbVie and Celgene 4The Zacks Analyst Blog Highlights: Biogen, Gilead, Puma Biotechnology, AbbVie and Celgene 5The Zacks Analyst Blog Highlights: Biogen, Gilead, Puma Biotechnology, AbbVie and Celgene 6Vermillion Sets Second Quarter 2014 Conference Call for Thursday, August 14, 2014 2TB Alliance Appoints Willo Brock Senior Vice President, External Affairs 2
... 1 The Michael J. Fox Foundation for ... to $6.5 million in total funding available under ... solutions to some of the most difficult hurdles ... PD.The Critical Challenges funding opportunities focus research efforts ...
... 31 Successful and seamless completion of clinical trial ... market research, an effective recruitment strategy, and project management ... Liz Moench notes: "This is achievable when clinical trial ... adds, "We had great team chemistry with the study ...
Cached Medicine Technology:Michael J. Fox Foundation Commits up to $6.5 Million in Funding for Critical Challenges in Parkinson's Disease 2Michael J. Fox Foundation Commits up to $6.5 Million in Funding for Critical Challenges in Parkinson's Disease 3Major Restless Legs Study Completes Enrollment With Support From MediciGlobal 2
(Date:7/31/2014)... 31, 2014 The 2013 edition ... about chemical listings, appellate decisions, litigation and settlement ... affect compliance with California's Proposition 65. , The ... law, regulations, history and trends impacting California's Proposition ... installment of the series which adds approximately 200 ...
(Date:7/31/2014)... (August 1, 2014) If you have asthma, you may ... to help you recognize and respond to changes and understand ... you,re in the green zone, you,re doing well, yellow means ... means you require urgent care. New guidelines are now available ... zone, back into green and away from the red zone. ...
(Date:7/31/2014)... Developer Jamestown, L.P., has been using ... City Market project in Atlanta’s Old Fourth Ward, which ... building into best-in-class office, housing, and retail spaces. As ... with their construction webcam service to assess how it ... construction camera for monitoring and documentation purposes, ...
(Date:7/31/2014)... Hoping to attract new customers who are ... , NutriGold is ready to ship out free samples of ... advantage of this offer fast and easy: http://www.nutrigold.com/Free-Samples ... at NutriGold, "We know that every time customers purchase one ... precious asset: their own health or the health of a ...
(Date:7/31/2014)... has announced that they are now offering a new ... Review of Sexual Satisfaction . The course is ... Clinical and Health Psychology. , This CE course has ... accurate information about sexual satisfaction so that healthcare professionals ... provides a systematic review of 197 research publications in ...
Breaking Medicine News(10 mins):Health News:Save 25% on the Proposition 65 Handbook - 2013 Edition Through August 31 2Health News:OxBlue Construction Webcam Proves Valuable Tool for Developer, Consumers on Historic Ponce City Market Project 2Health News:OxBlue Construction Webcam Proves Valuable Tool for Developer, Consumers on Historic Ponce City Market Project 3Health News:NutriGold Launches Product Samples Page for its Supplements 2Health News:NutriGold Launches Product Samples Page for its Supplements 3Health News:Company Provides New Course on Sexual Satisfaction 2Health News:Company Provides New Course on Sexual Satisfaction 3
... ... with GFK Custom Research North America, selected Warady & Davis LLP, Certified Public Accountants ... Chicago based on its innovative internships, "W&D University" training program, flexible scheduling, great team ... ...
... Oct. 28 The Board of Directors of Healthcare Trust ... of October, November, and December 2009. These distributions will ... during such month and will equal a 7.25% annualized rate ... The payment date for each of the daily distributions for ...
... , DENVER, Oct. 28 Many medical practices are ... are making basic business mistakes, according to Andrew Graham, ... the top reasons practices struggle, said Graham. , ... needs to include goals for revenue generation, customer service, ...
... for the third quarter ended September 30, 2009. Financial highlights from continuing operations for the third quarter of 2009 compared to ... in millions, except per share amounts), ... ... ...
... supply and demand starting to close, U.S. officials say, ... reported Wednesday the addition of another million doses H1N1 ... 23.2 million doses. , "We know people are ... now," Janet Napolitano, secretary of the U.S. Department of ...
... Application provides ... ... Harvard Health Publications Division of Harvard Medical School has launched an iPhone application focused ... knowledge of the experts at Harvard Medical School along with its long-standing expertise in publishing ...
Cached Medicine News:Health News:Warady & Davis LLP Named One of 'Top 50 Employers for Generation Y Chicago' 2Health News:Warady & Davis LLP Named One of 'Top 50 Employers for Generation Y Chicago' 3Health News:Board of Directors Declares Cash Distributions 2Health News:The Top 10 Business Mistakes Made By Physician Practices 2Health News:Carriage Services Announces Third Quarter 2009 Results 2Health News:Carriage Services Announces Third Quarter 2009 Results 3Health News:Carriage Services Announces Third Quarter 2009 Results 4Health News:Carriage Services Announces Third Quarter 2009 Results 5Health News:Carriage Services Announces Third Quarter 2009 Results 6Health News:Carriage Services Announces Third Quarter 2009 Results 7Health News:Carriage Services Announces Third Quarter 2009 Results 8Health News:Carriage Services Announces Third Quarter 2009 Results 9Health News:Carriage Services Announces Third Quarter 2009 Results 10Health News:Carriage Services Announces Third Quarter 2009 Results 11Health News:Carriage Services Announces Third Quarter 2009 Results 12Health News:Carriage Services Announces Third Quarter 2009 Results 13Health News:Carriage Services Announces Third Quarter 2009 Results 14Health News:Carriage Services Announces Third Quarter 2009 Results 15Health News:Carriage Services Announces Third Quarter 2009 Results 16Health News:Carriage Services Announces Third Quarter 2009 Results 17Health News:Carriage Services Announces Third Quarter 2009 Results 18Health News:Carriage Services Announces Third Quarter 2009 Results 19Health News:Carriage Services Announces Third Quarter 2009 Results 20Health News:1 Million More Doses of Swine Flu Vaccine on Hand 2Health News:Harvard Health Publications Launches H1N1 Flu iPhone Application 2Health News:Harvard Health Publications Launches H1N1 Flu iPhone Application 3
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: